Literature DB >> 21632709

Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments.

Neda Nikbakht1, Thi-Sau Migone, Chris P Ward, Tim Manser.   

Abstract

The peripheral B cell prosurvival cytokine BAFF/B lymphocyte stimulator (BLyS) has been proposed to participate in the regulation of immunological tolerance. Selective elimination or reconstitution of B cells expressing transgene-encoded, autoreactive BCRs upon systemic BLyS depletion or supplementation, respectively, was observed in two separate studies. Such findings led to a model positing a higher dependency of autoreactive B cells on BLyS. We tested this model by exploiting two targeted IgH transgenic mice (H chain knock-in [HKI]) that produce large numbers of follicular (FO) B cells that are either weakly or strongly autoreactive with nuclear autoantigens. Even though HKI B cells do not exhibit classical features of anergy, we found that mature, naive, autoreactive HKI B cells are outcompeted for representation in the periphery by a polyclonal B cell population. However, this is not due to a higher dependency of HKI B cells on BLyS for survival. Additionally, excess BLyS does not rescue HKI B cells from selective elimination. These findings suggest that some autoreactive FO B cells can fully develop while in competition with non-autoreactive cells for BLyS, but remain at a competitive disadvantage for other trophic factors that regulate peripheral stability. As such, our data indicate the existence of peripheral tolerance mechanisms that regulate the frequency of autoreactive FO B cells independent of the BLyS pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632709      PMCID: PMC3119736          DOI: 10.4049/jimmunol.1003924

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.

Authors:  Benjamin L Hsu; Susan M Harless; R Coleman Lindsley; David M Hilbert; Michael P Cancro
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

2.  Different sensitivity to receptor editing of B cells from mice hemizygous or homozygous for targeted Ig transgenes.

Authors:  U Braun; K Rajewsky; R Pelanda
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

3.  Resource competition determines selection of B cell repertoires.

Authors:  R J De Boer; A A Freitas; A S Perelson
Journal:  J Theor Biol       Date:  2001-10-07       Impact factor: 2.691

4.  Regulation of the B cell receptor repertoire and self-reactivity by BAFF.

Authors:  Miyo Ota; Bao H Duong; Ali Torkamani; Colleen M Doyle; Amanda L Gavin; Takayuki Ota; David Nemazee
Journal:  J Immunol       Date:  2010-09-03       Impact factor: 5.422

5.  Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation.

Authors:  D Allman; R C Lindsley; W DeMuth; K Rudd; S A Shinton; R R Hardy
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

6.  An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.

Authors:  B Schiemann; J L Gommerman; K Vora; T G Cachero; S Shulga-Morskaya; M Dobles; E Frew; M L Scott
Journal:  Science       Date:  2001-08-16       Impact factor: 47.728

7.  Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.

Authors:  Elizabeth A Leadbetter; Ian R Rifkin; Andreas M Hohlbaum; Britte C Beaudette; Mark J Shlomchik; Ann Marshak-Rothstein
Journal:  Nature       Date:  2002-04-11       Impact factor: 49.962

8.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice.

Authors:  S D Khare; I Sarosi; X Z Xia; S McCabe; K Miner; I Solovyev; N Hawkins; M Kelley; D Chang; G Van; L Ross; J Delaney; L Wang; D Lacey; W J Boyle; H Hsu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

9.  Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.

Authors:  F Mackay; S A Woodcock; P Lawton; C Ambrose; M Baetscher; P Schneider; J Tschopp; J L Browning
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

10.  Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen.

Authors:  P Schneider; H Takatsuka; A Wilson; F Mackay; A Tardivel; S Lens; T G Cachero; D Finke; F Beermann; J Tschopp
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  12 in total

Review 1.  The rationale for BAFF inhibition in systemic lupus erythematosus.

Authors:  Anne Davidson
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

Review 2.  Here, There, and Anywhere? Arguments for and against the Physical Plasma Cell Survival Niche.

Authors:  Joel R Wilmore; David Allman
Journal:  J Immunol       Date:  2017-08-01       Impact factor: 5.422

Review 3.  Future prospects in biologic therapy for systemic lupus erythematosus.

Authors:  William Stohl
Journal:  Nat Rev Rheumatol       Date:  2013-09-10       Impact factor: 20.543

Review 4.  BAFF inhibition in SLE-Is tolerance restored?

Authors:  Shaun W Jackson; Anne Davidson
Journal:  Immunol Rev       Date:  2019-09-28       Impact factor: 12.988

5.  BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus.

Authors:  Weiqing Huang; Ioana Moisini; Ramalingam Bethunaickan; Ranjit Sahu; Meredith Akerman; Dan Eilat; Martin Lesser; Anne Davidson
Journal:  J Immunol       Date:  2011-11-18       Impact factor: 5.422

6.  The discovery and development of belimumab: the anti-BLyS-lupus connection.

Authors:  William Stohl; David M Hilbert
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

Review 7.  Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

8.  The Effect of BAFF Inhibition on Autoreactive B-Cell Selection in Murine Systemic Lupus Erythematosus.

Authors:  Alexis Boneparth; Megan Woods; Weiqing Huang; Meredith Akerman; Martin Lesser; Anne Davidson
Journal:  Mol Med       Date:  2016-02-12       Impact factor: 6.354

9.  B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord injury-induced autoimmunity.

Authors:  Jonah W Saltzman; Ricardo A Battaglino; Loise Salles; Prateek Jha; Supreetha Sudhakar; Eric Garshick; Helen L Stott; Ross Zafonte; Leslie R Morse
Journal:  J Neurotrauma       Date:  2013-03-28       Impact factor: 5.269

10.  Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.

Authors:  Weiqing Huang; Tam D Quach; Cosmin Dascalu; Zheng Liu; Tungming Leung; Miranda Byrne-Steele; Wenjing Pan; Qunying Yang; Jian Han; Martin Lesser; Thomas L Rothstein; Richard Furie; Meggan Mackay; Cynthia Aranow; Anne Davidson
Journal:  JCI Insight       Date:  2018-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.